|Mr. James R. Sapirstein||CEO & Director||596.64k||N/A||1961|
|Dr. Theresa Matkovits||Chief Operating Officer||250k||N/A||1967|
|Dr. John Z. Sullivan-Bolyai||Part-Time Consultant & Member of Scientific Advisory Board||320k||N/A||1948|
|Mr. John T. Cavan||Chief Financial Officer||N/A||N/A||1958|
|Dr. Robert T. Foster BSc (Pharm), Pharm.D., Ph.D.||Chief Scientific Officer||N/A||N/A||1958|
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. The company was founded in 2013 and is headquartered in Edison, New Jersey.
ContraVir Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.